Tong Xiao Lin, an academician of the Chinese Academy of Sciences, is a traditional Chinese medicine internal medicine specialist, and the director of the National Center for Chinese and Western Medicine Integration. He has long been committed to the inheritance and innovative research of traditional Chinese medicine, and has integrated Chinese medicine concept of “State-modulation” with the Western medicine concept of “Targets” strategy. He first proposed the concept of “State-target differentiation and treatment” and restructured a new system for traditional Chinese medical diagnosis and treatment. He established a new system for traditional Chinese medical diagnosis and treatment for diabetes with the framework of “core pathogenesis-classification-stage and syndrome differentiation”. He won the He Liang He Li Science and Technology Progress Award and the National Science and Technology Progress Second Prize.

He has pioneered the reconstruction of the modern herbal system of traditional Chinese medicine, integrated the pharmacological targets of Chinese medicine and the traditional theory of drug properties, and achieved “mutual adjustment of State-target”. He has revealed the laws of “quantity-induced innovation” and “quantity-induced counteraction”, and constructing a theoretical framework for the efficacy and dosage of herbal formulas with “individualized dosing and dosage threshold” as the core, laying an important foundation for promoting Chinese medicine into the “quantitative” era.

During the COVID-19 pandemic, as the leader of the national Chinese medicine medical rescue expert group, the leader of the Chinese medicine epidemic prevention and control expert committee of the National Administration of Traditional Chinese Medicine, and the leader of the central aid Hong Kong anti-epidemic expert group, he went to the front line of the epidemic in 12 provinces and Hong Kong Special Administrative Region to guide rescue work. He innovatively constructed the “Wuchang model” for community prevention and control, formulated the general treatment method “Hanshiyi Formula (Wuhan Anti-epidemic No.1 Formula)”, developed the first listed new medicine “Sanhan Huashi Granules” for cold and damp epidemic diseases, and formulated and launched the “four plans” for COVID-19 treatment, making significant contributions to epidemic prevention and control work. He was awarded the national “Most Beautiful Science and Technology Worker” by the Central Propaganda Department and other departments, the “National Innovation and Advancement Award Medal” by the Ministry of Human Resources and Social Security, and the “National Advanced Individual in Fighting COVID-19” by the CPC Central Committee and other honors.